We would love to hear your thoughts about our site and services, please take our survey here.
Trek, I have previously said 'each to their own' about you which I stand by, however, this board is about PHNX the company and not about trading strategies all the time. If I wanted to read that I'd simple go to the AIM rubbish stocks and read that style of posts. It is a shame you feel the desire to justify everything you do or do not so.
Phnx as a company has been around a very long time with a good pedigree, decent free cash flow and a great yield. I am down short term but remain relaxed as I know it is just a matter of holding for a few years and watching the power of compounding give me (hopefully) a very decent return. There is another way of protecting capital and that is investing in great companies or funds and riding the waves, all about timescales. Your way is your way, but others do things differently what matters is the health and potential of the company, which, in my view remains sound as my pound. GLA
make of it what you will but in the absence of any rns or capital market day that i know of it seems a back of a *** packet view to be honest:
'double-downgrade' from barclays.
the investment banking arm of the high-street lender moved to 'underweight' on stock in the long-term savings and retirement group with a price target of £5 a share.
in a brief note, it said: "phoenix faces insufficient cash from operations alone to support management's targets, a weaker capital position than peers, and a change in strategy from historical areas of strength to areas where the group is not meaningfully differentiated, in our view. targets may only be fully evident in 2027."
Https://www.polarean-ir.com/docs/librariesprovider37/archive/admission-doc.pdf
page 16 and page 50 are the key areas.
Los ... That is simple wrong. Read the IPO admission document and see the breakdown of the patents, expiry's and licence agreements. Duke own the vast majority and a lot due to expire in the next few years, hence hatchwaxman application and protection. There is a reason the CTO is from Duke and it involves risk free funding streams for their research. Polx own parts of the polariser but not the methodology. The IPO doc is detailed, as it had to be transparent from them to be listed. A company website... well ..enough said.
Different strategy for me...fully loaded for the following reasons:
1. Yield is covered and dividend policy will be progressive.
2. The company balance sheet will continue to generate FCF given forward earnings not accounted for
3. unemployment rate up and inflation nailed on to be lower tomorrow putting pressure on BofE
4. £ taking a hit and increasingly attractive returns to US based investors after their index meltdown
5. I just like the company
GLA
Proactive Investors - A competition probe into Britain’s veterinary market is unlikely to hit CVS Group (LON:CVSG) and Pets at Home Group PLC (LON:PETSP) as hard as feared, analysts have reassured.
The Competition and Markets Authority would likely look to enforce more transparency, rather than taking drastic measures such as forcing disposals and capping product prices, Liberum analysts said in a note.
“The main remedies are likely to be around information disclosure and there is nothing to stop the industry adopting those changes ahead of time,” the bank reassured, having interviewed the regulator’s ex-legal head, Tom Smith.
“The read across for CVS is perhaps less significant than one might have thought and contrary to some commentators, we don’t think that CVS is dead money.
“For Pets at Home, the impact is likely to be negligible with its differentiated model insulating it to a large degree.”
Britain’s CMA launched an investigation into the pet medicines and treatment market last month, warning owners were often uninformed on pricing and could be overpaying as a result.
AIM-listed vet service provider CVS Group took a hit on the news, having responded saying it had already proposed a “package of possible remedies” to the CMA.
Pets at Home assured the investigation was unlikely to find it at fault meanwhile, since the retailer’s sites run as joint ventures and are independently responsible for pricing.
Liberum, quoting Smith, argued that competition concerns were likely more a result of consumers not shopping around, given the often stressful nature of seeking pet care.
“If your dog is sick, you just want to get it sorted out,” as per Smith, “you don't want to go and shop around at four different vets to get different prices”.
Remedies are likely to tackle the lack of information on rival services and products, therefore, as per Liberum.
CVS climbed 2.4% to 967p on the news, while Pets at Home gained 1.1% to reach 268.59p.